Meeting
2023 ASCO Annual Meeting
A phase III, multicenter, double-blinded, randomized, active-controlled study on the efficacy and safety of QL1706 with chemotherapy (CT) as first-line therapy for PD-L1–negative advanced or metastatic non–small-cell lung cancer (NSCLC).
Authors
Li Zhang
Department of Medical Oncology, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Li Zhang , Yan Huang , Lianghua Fang , Huayuan Wang , Cuicui Han , Xiaoyan Kang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Biologic Correlates
Clinical Trial Registration Number
NCT05690945
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS9139)
DOI
10.1200/JCO.2023.41.16_suppl.TPS9139
Abstract #
TPS9139
Poster Bd #
127a
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients (pts) with metastatic non–small cell lung cancer (NSCLC): 3-year update from CheckMate 9LA.
First Author: Luis G. Paz-Ares
Poster
2016 ASCO Annual Meeting
Phase III clinical trials of atezolizumab combined with chemotherapy in chemotherapy-naive patients with advanced NSCLC.
First Author: Vassiliki Papadimitrakopoulou
Poster
2024 ASCO Breakthrough
SUNRAY-01, a pivotal, global study of olomorasib (LY3537982) in combination with pembrolizumab with or without chemotherapy for 1L treatment in KRAS G12C-mutant advanced NSCLC.
First Author: Makoto Nishio
Poster
2023 ASCO Annual Meeting
Phase II trial of safety and efficacy of tislelizumab plus chemotherapy in stage II-IV non small cell lung cancer (LungMark).
First Author: Yaobin Lin